Venmax Drugs and Pharmaceuticals Shareholders Approve Amalgamation

Total Valid Votes Cast: 72,10,542 | Approval Rate: 99.9979%

Reader Takeaway: Strong shareholder backing for the Hatri Pharma merger removes a key hurdle for Venmax Drugs' consolidation strategy.

What just happened

Venmax Drugs and Pharmaceuticals successfully secured shareholder approval for its scheme of amalgamation with Hatri Pharma Private Limited. During an NCLT-convened meeting held via video conferencing on October 24, 2026, the resolution received near-unanimous support. Out of 72,10,542 total valid votes cast, 72,10,392 were in favor, while only 150 votes were cast against the proposal.

Why this matters

The approval marks a significant step in the company's restructuring plan initiated earlier this year. As a requirement under Sections 230 to 232 of the Companies Act, 2013, the shareholder nod allows Venmax Drugs to move forward with the next stage of the legal and regulatory process mandated by the NCLT, Hyderabad Bench-II. The amalgamation aims to integrate Hatri Pharma into the operations of Venmax Drugs, potentially altering the company's consolidated business footprint.

The backstory

The process follows an initial filing dated September 8, 2026, outlining the merger structure between the two entities. Ms. Kruthi Kalaga served as the court-appointed scrutinizer to ensure transparency and compliance throughout the e-voting process, which included both remote e-voting and e-voting conducted during the meeting session.

What to track next

Investors should monitor subsequent filings regarding final NCLT orders and the formal date of effectiveness for the merger. Following the final court order, the company will likely provide updates on share exchange ratios or operational integration timelines if applicable.